We’ve Launched Our 2020 National Report Card
HAE Canada sent all our members links to the 2020 National Report Card survey. This important survey will allow HAE Canada to understand patient product use so we may continue to advocate for improved access to new, and current, safe and effective HAE treatments.
This information will aid in our current Advocacy campaign to list HAEGARDA through CBS and to expedite access to TAKHZYRO through the many Provincial and Federal Jurisdictions. We also require this data to show a need for Canadian research for HAE with normal C1.
Only HAE Canada members can fill out the survey. If you are a member and you did not receive the survey, please email office@haecanada.org to request your link. If you are or care for a HAE patient, please consider joining HAE Canada and fill out the survey.
Completing this survey will also give members a chance to win a travel grant to attend the next HAEi Global Conference.
Latest News
Lanadelumab Added to NS Formulary
Lanadelumab (TAKHZYRO), a treatment to routinely prevent attacks in patients with HAE Type I or II who are 12 years old and up, was recently added to Nova
Congratulations Heather Dow
Who is Heather Dow? Heather has been supporting HAE Canada in many ways over the years, from providing technical support for our virtual Patient Information Updates and organizing
Winning the HAE Global Walk
Congratulations to the Canadian HAE Community! Canadians logged the most steps to win the 2021 Global Walk for a third time. Thank you very much to all who
2021 HAE Day 🙂
Happy HAE Day and Happy 10th Anniversary! We hope everyone celebrated HAE Day 🙂 by doing something extra fun. Did you go for a hike? Did you plant
TAKHZYRO: Available in Saskatchewan
HAE Canada is happy to share that Saskatchewan is the latest province to add lanadelumab (TAKHZYRO), a subcutaneous preventative HAE treatment, to their provincial drug formulary. Please click
HAEGARDA: Available Across Canada
We are over the moon that our members are telling us that they are excited about having access to HAEGARDA, a subcutaneous C1 esterase inhibitor (C1-INH) prophylaxis therapy
TAKHZYRO now available in Newfoundland & Labrador
We love sharing amazing news, and now we have even more to love! On March 17th, 2021, lanadelumab (TAKHZYRO), a subcutaneous monoclonal antibody inhibitor of plasma kallikrein, was
April 6 is the day for HAEGARDA in Canada!
We are thrilled to let you know that starting April 6, HAEGARDA, a subcutaneous C1 Esterase Inhibitor (human), manufactured by CSL Behring, will be included on the Canadian Blood
Takhzyro Added to the NIHB Formulary
We are happy to share that eligible HAE patients across Canada who have coverage under the Non-Insured Health Benefits (NIHB) for First Nations and Inuit Program can now
Takhzyro soon available in Manitoba
Great news for eligible HAE patients in Manitoba! Starting April 1, 2021, Manitoba Pharmacare will list lanadelumab (Takhzyro) as part of Exception Drug Status. To find out more,
Takhzyro is now available in BC
Have you heard the latest fantastic news? British Columbia has recently started providing access to lanadelumab (TAKHZYRO) to eligible HAE patients. For further details and to learn how
Ontario is the latest province to provide access to Takhzyro!
We are excited to share that Ontario is the latest province to provide access to lanadelumab (TAKHZYRO) to HAE patients. When the Ontario Ministry of Health issued its
New Brunswick has added TAKHZYRO to their Provincial Drug Plan!
Another province has added TAKHZYRO to their provincial formulary! As of January 27th, 2021, Type I & II HAE patients in New Brunswick have access to lanadelumab (Takhzyro)
Takeda’s Patient Resource myHAEcheckup.ca is now available!
You deserve to live your best life. However, living with HAE can be difficult, even between attacks. Takeda Inc. is introducing a new, comprehensive resource designed to help
A New CSL Behring Patient Support Program
We wanted to let our members know that starting February 1st, 2021, CSL Behring patient support programs (Hizentra™ CARE Program, and Berinert® Assistance Program) will be streamlined into
Have no fear, the COVID vaccine is safe
Recently, HAE International's President and CEO, Tony Castaldo interviewed Prof. Dr. Marcus Maurer to discuss HAE patients and the COVID vaccine. We encourage everyone to please watch this
TAKHZYRO Now Available in Alberta
We are thrilled to share that as of December 1st, 2020, Type I & II HAE patients in Alberta have access to lanadelumab (Takhzyro) through the province's Drug
TAKHZYRO: One Step Closer
Amazing news! Canadian HAE patients are one step closer to gaining equitable access to the new treatment, TAKHZYRO! After months of negotiations, Takeda Canada announced it has completed
Terrific News for HAE Patients in Quebec
We have some exciting news to share! We are pleased to let everyone know the Institut national d’excellence en santé et en services sociaux (INESSS) has reevaluated lanadelumab
Canada Won the 2020 HAE Global Walk
Thank you to the amazing HAE Community here in Canada - Canada won the Virtual 2020 HAE Global Walk; an annual event organized by the HAE International team.
Great News!
HAEGARDA and TAKHZYRO are now available in Canada. Please talk to your HAE specialist about access. Thank you Canadian Blood Services (CBS) for a very collaborative, informative and
HAE Day 2020
For HAE Day 2020, HAE Canada wants to celebrate! To honour the day we have two BIG announcements: 1) Our website received a facelift! We hope our
Virtual HAE Global Walk
It’s time, once again, for HAE Canada to please ask you to take out your walking shoes and participate in the virtual HAE Global Walk arranged by HAE
HAE Canada’s message on COVID-19
HAE Canada continues to remain focused on the health and well-being of patients with hereditary angioedema, and other related angioedema, in Canada. We would like to share what
Support Family Testing
Give valuable insights in HAE science
Hereditary Angioedema (HAE) is a hereditary disorder. It is therefore very important to have other family members tested. To help you in this process HAE International has developed two documents for patients. You can download the documents below:
